BiBo Pharma

With biologics manufacturing in a Fourth Wave of innovation, the industry is preparing for a seismic shift in pharmaceutical development and patient care. With projections placing the biologics market at US$1.14 trillion by 2034, this CPHI Online Trend Report, in collaboration with BiBo Pharma, uncovers how this Fourth Revolutionary Wave of biologics manufacturing is transforming patient access to life-changing therapies. In this report, discover expert insight from industry leaders on: Manufacturing Excellence – production innovations reducing costs to as low as US10 per gram Talent Acquisition Strategies – addressing the critical skills gap in specialised biologics production Regulatory Navigation – balancing compliance with accelerated time-to-market Global Market Access – strategies for penetrating emerging markets in APAC and beyond With contributions from pharmaceutical professionals at BiBo Pharma, Team Consulting, Lead Candidate, and Ecolab, download the full Trend Report to unlock strategies driving the future of biologics manufacturing, enabling access to billion-dollar drugs for billions of patients.

The presentation explores the rapidly growing biologics market and addresses poor accessibility challenges through breakthrough solutions, including an ultra-large scale production line, innovative manufacturing processes featuring Epic-CHO® Cell Line and Grand-CHO® Platform, and revolutionary Panflex®-Engineering technology. These advancements create a pathway to $10/g biologics production, leading to the "BiBo Moment" that reshapes the biomanufacturing landscape through differentiated advantages and represents the fourth revolutionary wave of biologics manufacturing.